The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma : Episode 4

Opinion

Video

April 23, 2024

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Author(s):

Richard Finn, MD,David James Pinato, MD, MRCP, PhD

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

EP: 1.Examining the Role of Liver Function in HCC

EP: 2.HCC Staging: Improving Treatment Strategies

EP: 3.Locoregional Therapies for Intermediate-Stage HCC

Now Viewing

EP: 4.HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

EP: 5.Emerging Therapies in Intermediate-Stage HCC

EP: 6.Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP: 7.Comorbidity Considerations for HCC Treatment

EP: 8.The Evolving Landscape of Second-Line Therapies in HCC Management

EP: 9.Additional Second-Line Treatments for HCC

EP: 10.Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 11.Pioneering Breakthroughs in HCC Treatment

Related Content

January 5th 2025

Patient Factors Drive IO Combination Selection in Unresectable HCC

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine

August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Penpulimab Plus Anlotinib for Advanced HCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

November 26th 2024

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

November 25th 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center

November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC